The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Investing in high-yield stocks with solid dividend payouts and a history of dividend growth can help investors collect ...

While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative acquisition, and it projects Seagen to contribute $10 billion in sales by 2030.

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...

Pfizer ($PFE) has long been a staple in the portfolios of income-oriented investors, especially those drawn to its consistent ...

Starboard Value, an activist investment firm, has taken a significant $1 billion stake in Pfizer, signaling its intent to ...